LV internal dimensions

LVIDd, LVIDs · PLAX end-diastole and end-systole, 2D-guided, inner-edge to inner-edge, below the mitral leaflet tips

Normal range & thresholds

	Men	Women
LVIDd	42–58 mm	38–52 mm
LVIDs	25–40 mm	22–35 mm
LVIDd indexed	2.2–3.1 cm/m²	2.3–3.1 cm/m²

European reference ranges from the NORRE study are closely comparable.^[97] Fractional shortening (LVIDd−LVIDs)/LVIDd normal 25–45% — but it samples one basal segment only and must never substitute for ejection fraction when wall motion is regional.^[1]

Pathophysiology

End-diastolic dimension is a preload and chronic-volume-overload variable: it tracks the total diastolic volume the ventricle has had to accommodate. End-systolic dimension is far closer to a contractility and afterload variable, because it is measured at the point where the ventricle has finished ejecting against the load. That is precisely why every regurgitant-lesion guideline hangs its surgical trigger on LVESD, not LVEDD: in mitral regurgitation the low-impedance leak flatters ejection fraction, and end-systolic size is the first structural sign that contractility is failing.^[7,91]

Raised by

Volume overload — chronic severe AR, chronic severe primary MR, VSD/PDA, high-output states
Dilated cardiomyopathy — genetic, alcoholic, peripartum, chemotherapy, myocarditic, tachycardia-induced, thyroid
Ischaemic remodelling after large anterior infarction
Athlete’s heart (endurance) — dilated but with normal or supranormal function and normal filling
Bradycardia, complete heart block, severe bradyarrhythmia (long filling period)
Anaemia, thyrotoxicosis, pregnancy, arteriovenous fistula, beri-beri, cirrhosis
Left bundle branch block and chronic RV pacing

Lowered by

Small body habitus — index before interpreting
HCM and hypertensive concentric remodelling (small, thick-walled cavity)
Restrictive and infiltrative cardiomyopathy, endomyocardial fibrosis
Hypovolaemia, dehydration, post-dialysis, aggressive diuresis
Cardiac tamponade and constrictive pericarditis
Severe mitral stenosis (underfilled LV)
Severe pulmonary hypertension / RV pressure overload with septal shift and D-shaped LV
Large pleural effusion or mediastinal mass compressing the heart

Technique & pitfalls

End-diastole = onset of QRS or largest cavity; end-systole = smallest cavity, not the aortic-valve-closure frame.
2D-guided, perpendicular to the long axis, immediately below the mitral leaflet tips — the same level at both ends of the cycle.
Index to BSA before drawing conclusions, and say so in the report; this matters enormously in short women, in whom absolute LVESD is falsely reassuring.
In an asymmetric or aneurysmal ventricle, a single linear dimension is meaningless — report volumes.
Serial follow-up demands identical technique; changes of <3 mm are within test–retest variability.

Pseudo-change & artefact

Oblique planes — both overestimation (tangential cut) and underestimation (foreshortening).
Measuring at the papillary muscle level instead of the mitral tip level.
Loading: 3–5 mm swing in LVIDd across a dialysis session or after intravenous diuresis — so ‘improvement’ on a post-diuresis study may be entirely volume.
Heart rate and rhythm: the post-extrasystolic beat is larger; in AF, average 5–10 cycles.
Tachycardia truncates diastole and shrinks LVIDd.
M-mode-only measurement without 2D guidance.

Treatment thresholds

Chronic severe aortic regurgitation: LVESD >50 mm or LVESD index >25 mm/m² → AVR even if asymptomatic (class I, 2020 ACC/AHA); LVEDD >65 mm is a class IIb trigger.^[7]
2025 ESC/EACTS — asymptomatic severe AR: surgery for LVESDi >22 mm/m², or LVESVi >45 mL/m², or LVEF ≤55% at low operative risk — a deliberate lowering of the dimensional trigger.^[6]
Asymptomatic severe primary MR: LVESD ≥40 mm → surgery (class I); the 2025 ESC/EACTS guidelines add LVESDi ≥20 mm/m², which rescues the small patient whose absolute dimension never reaches 40 mm.^[6,7]
Atrial secondary MR is defined in part dimensionally: LVEDD <56 mm (women) / <63 mm (men) with LVEF ≥50% and no regional wall motion abnormality.^[6]
Dilated cardiomyopathy diagnosis requires LV dilatation (>2 SD for BSA and sex) with reduced systolic function.^[14]

Next step

Next: index to BSA, then convert to biplane volumes — volumes are what the guidelines have moved to.
Then: global longitudinal strain, which falls before LVESD reaches its threshold and identifies the regurgitant patient who is already decompensating.^[108]
Then: CMR for accurate volumes, tissue characterisation and aetiology when echo is discordant or the cause is unclear; exercise echocardiography if symptoms and dimensions disagree.
Then: in volume-overload lesions, shorten the surveillance interval to 6 months once dimensions approach threshold, and refer to a Heart Team before the threshold is crossed.

Drugs

Quadruple GDMT in HFrEF is the reverse-remodelling therapy: ARNI, beta-blocker, MRA, SGLT2 inhibitor.^[11,12]
Sacubitril/valsartan: LVEDV index −7.9 mL/m² and LVESV index −7.5 mL/m² at 12 months (PROVE-HF).^[68]
Empagliflozin: LV end-diastolic volume −25.1 mL and LV mass −17.8 g at 6 months in non-diabetic HFrEF (EMPA-TROPISM).^[69]
Beta-blockers reduce LV dimensions over 3–6 months; ivabradine helps when heart rate remains high.
Vasodilators do not substitute for surgery in asymptomatic severe AR or MR with dilated dimensions.

Reversibility

Non-ischaemic DCM: meaningful reverse remodelling in ≈40% on modern GDMT within 6–12 months; TRED-HF showed that 44% relapse within 6 months of withdrawing therapy, so recovery is drug-dependent remission, not cure.^[70,71]
Primary MR after repair: LVEDD falls rapidly (days to weeks) as the leak is abolished; LVESD falls little, and a pre-operative LVESD ≥40–45 mm predicts persistent post-operative dysfunction — the volume was reversible, the contractile loss was not.^[91,92]
Chronic AR after AVR: most of the reduction happens in the first 6 months; normalisation is the rule when pre-operative LVESD <50 mm and uncommon above 55 mm.^[94,95]
Tachycardia-induced: near-complete normalisation within 3–6 months of rate/rhythm control.